Best Treatment for Hormonal Acne
For hormonal acne, combined oral contraceptives (COCs) containing drospirenone are the first-line treatment option for women who also desire contraception, while spironolactone is the preferred treatment for women who do not need contraception. 1, 2
First-Line Treatment Options
Combined Oral Contraceptives (COCs)
FDA-approved COCs for acne treatment include:
Mechanism of action:
Clinical considerations:
Spironolactone
Mechanism: Aldosterone receptor antagonist with potent antiandrogen activity 1
Dosage: 50-100 mg daily is effective with favorable tolerability 1
Benefits:
Safety considerations:
Treatment Algorithm
For Women Desiring Contraception:
- First choice: Drospirenone-containing COC (e.g., Yaz/Yasmin) 2, 3
- Alternative options:
- For inadequate response after 3-6 months: Add spironolactone 50-100 mg daily 1
For Women Not Desiring Contraception:
- First choice: Spironolactone 50-100 mg daily 1
- For inadequate response: Consider adding topical treatments (retinoids, benzoyl peroxide) 1
Topical Treatment Options
- Can be used as adjuncts to hormonal therapy:
Important Safety Considerations
COC Contraindications:
- History of deep vein thrombosis or pulmonary embolism 2, 4
- Uncontrolled hypertension 4
- Smoking in women over 35 years 4
- Current breast cancer 4
- Severe liver disease 4
- Migraine with aura 2, 4
Venous Thromboembolism (VTE) Risk:
- Baseline risk (non-pregnant, non-COC users): 1-5 per 10,000 woman-years 2
- Risk with standard COCs: 3-9 per 10,000 woman-years 2
- Risk with drospirenone-containing COCs: approximately 10 per 10,000 woman-years 2
- For context, pregnancy VTE risk: 5-20 per 10,000 woman-years 2
Common Pitfalls to Avoid:
- Avoid progestin-only contraceptives as they may worsen acne 1, 2
- Don't expect immediate results with hormonal therapy; improvement takes 3-6 months 1
- Don't withhold COCs from appropriate candidates due to misconceptions about antibiotic interactions - only rifampin and griseofulvin reduce COC effectiveness 1
- Don't routinely monitor potassium in young, healthy women on spironolactone without risk factors for hyperkalemia 1
Monitoring and Follow-up
- For COCs: Blood pressure measurement before initiation 1, 2
- For spironolactone: Consider potassium monitoring only in patients with risk factors for hyperkalemia (renal insufficiency, heart failure, concomitant medications like ACE inhibitors) 1
- Follow-up at 3 months to assess initial response and side effects 1
- Assess for maximal benefit at 6 months 1